Prometheus Laboratories Inc.
5739 Pacific Center Boulevard
San Diego
California
92121-4203
United States
Tel: 888-423-5227
Fax: 858-824-0896
Website: http://www.prometheuslabs.com/
Email: IR@Prometheuslabs.com
76 articles about Prometheus Laboratories Inc.
-
Prometheus Laboratories Announces Collaboration with Fresenius Kabi on Anser Testing
8/1/2023
Prometheus Laboratories Inc. today announced a collaboration with Fresenius Kabi to support the validation of and access to Anser therapeutic drug monitoring (TDM) services for eligible patients receiving the Fresenius Kabi biosimilar, IDACIO (adalimumab-aacf).
-
Prometheus Laboratories Announces the Launch of PredictrPK ADA, A Precision-Guided Dosing Test for Optimization of Adalimumab
7/27/2023
Prometheus Laboratories Inc. announced the launch of PredictrPK ADA, a precision-guided dosing test for adult Crohn's disease (CD) patients receiving ADA treatment.
-
Prometheus Launches New Indication for PredictrPK® IFX, A Precision-Guided Dosing Test for IBD
3/2/2023
Prometheus Laboratories Inc. ("Prometheus"), a leader in precision healthcare, announced the launch of an induction-phase indication for PredictrPK IFX, a precision-guided dosing test.
-
Prometheus Laboratories Announces Partnership with Takeda to Launch CDPATH™, a Personalized Prognostic Tool Advancing Innovation for Crohn's Disease Patients
9/14/2022
Prometheus Laboratories Inc. ("Prometheus") today announced its partnership with Takeda Pharmaceutical Company Limited ("Takeda") to nationally launch CDPATH, an innovative prognostic tool for Crohn's disease (CD) patients.
-
Prometheus Laboratories Announces the Launch of PredictrPK™ IFX, A Revolutionary Test Enabling Precision-Guided Dosing for Inflammatory Bowel Disease
2/17/2022
Prometheus Laboratories Inc., a leader of precision healthcare, announced the launch of PredictrPK IFX, a test that aids healthcare providers with biologic dose optimization through individualized pharmacokinetic modeling.
-
Prometheus Laboratories Announces Multiple Presentations on Precision-Guided Dosing and Monitoring at the Digestive Disease Week 2021 Annual Meeting
5/11/2021
Prometheus Laboratories, Inc. ("Prometheus"), a leader of precision healthcare, announced today multiple presentations and posters on precision-guided dosing and monitoring of Inflammatory Bowel Disease (IBD) at the virtual 2021 Digestive Disease Week
-
BioSpace scanned the WARN (Worker Adjustment and Retraining Notification) notices across the country and compiled a small list of recent layoffs across the industry.
-
A recent survey by the Pew Research Center found that 57 percent of Americans surveyed thought it was appropriate to use genetically engineered animals to grow organs for human transplants.
-
An article published earlier this summer in the Journal of Dental Research suggests that “bioengineered tooth buds” are a “superior alternative tooth replacement therapy.” In the article “Bioengineered Tooth Buds Exhibit Features of Natural Tooth Buds,” the authors report that artificial implants...
-
Prometheus Laboratories Release: New Test Monitors Therapeutic Ustekinumab Levels In IBD Patients
10/18/2017
Prometheus Laboratories Inc. announces a new therapeutic drug monitoring test for use in adult inflammatory bowel disease (IBD) patients treated with Stelara (ustekinumab).
-
Prometheus Laboratories Release: New Serum Test Is First to Measure and Monitor Mucosal Healing in Crohn's Disease
10/17/2017
Prometheus Laboratories introduces a comprehensive new serum test that measures and monitors mucosal healing status in Crohn's disease patients.
-
Noninvasive PROMETHEUS FIBROSpect NASH Test Measures Severity of Liver Fibrosis
10/17/2017
Prometheus Laboratories introduces the FIBROSpect NASH test, a new tool to help healthcare providers stratify NASH patients by risk, based on the severity of their liver fibrosis.
-
Prometheus Laboratories Inc. Release: Introducing PROMETHEUS IBcause: Convenient All-In-One Diagnostic Test For Persistent Diarrhea
3/28/2017
-
Prometheus Laboratories Inc. Release: PROMETHEUS Anser VDZ Test Validated For Use In Inflammatory Bowel Disease Patients
10/12/2016
-
Prometheus Laboratories Inc. Diagnostic Test Validated In Anticipation Of U.S. Healthcare Provider Demand For Celltrion's INFLECTRA (Biosimilar Infliximab)
4/8/2016
-
Prometheus Laboratories Inc. Release: PROCLAIM Patient Registry Data Demonstrates Safety And Efficacy Of Proleukin (Aldesleukin) When Sequenced With Immune Checkpoint Inhibitors In Metastatic Melanoma
5/28/2015
-
Prometheus Laboratories Inc. Release: PROCLAIM Patient Registry Data Demonstrate Survival Benefit Of First-Line Proleukin Therapy In Patients With Metastatic Renal Cell Carcinoma
5/28/2015
-
Prometheus Laboratories Inc. Release: New Data Show Proleukin (aldesleukin) Improves Patient Outcomes As First-Line Therapy For The Treatment Of Patients With Metastatic Melanoma Or Metastatic Renal Cell Carcinoma
5/15/2015
-
Prometheus Laboratories Inc. Release: PROCLAIM Patient Registry Data Show Extension Of Overall Survival Benefits Beyond Complete And Partial Responders In Metastatic Renal Cell Carcinoma Patients Treated With High-Dose Interleukin-2 (HD IL-2)
5/30/2014
-
Prometheus Laboratories Inc. Announces Inclusion of Proleukin® (Aldesleukin for Injection) / Interleukin-2 in SITC Guidelines for Treatment of Cutaneous Melanoma
10/11/2013